Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis

NCT06414954 is registered in ClinicalTrials.gov with NMD Pharma A/S as lead sponsor.

NCT NCT06414954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06414954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis
Lead sponsor
NMD Pharma A/S
Phase
Phase 2
Overall status
Recruiting
Start date
May 16, 2024
Completion date
December 31, 2026
Enrollment
84 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis, myasthenia gravis, musk